JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB4830

Anti-Cleaved PARP1抗体

Anti-Cleaved PARP1 antibody

5

(4 Reviews)

|

(69 Publications)

Rabbit Polyclonal PARP1 antibody. Suitable for WB and reacts with Human samples. Cited in 69 publications. Immunogen corresponding to Synthetic Peptide within Human PARP1.

查看别名

ADPRT, PPOL, PARP1, Poly [ADP-ribose] polymerase 1, PARP-1, ADP-ribosyltransferase diphtheria toxin-like 1, DNA ADP-ribosyltransferase PARP1, NAD(+) ADP-ribosyltransferase 1, Poly[ADP-ribose] synthase 1, Protein poly-ADP-ribosyltransferase PARP1, ARTD1, ADPRT 1

3 Images
Western blot - Anti-Cleaved PARP1 antibody (AB4830)
  • WB

AbReview4012****

Western blot - Anti-Cleaved PARP1 antibody (AB4830)

All lanes:

Western blot - Anti-Cleaved PARP1 antibody (ab4830) at 1/1000 dilution

Lane 1:

Non-induced Jurkat cells

Lane 2:

Induced Jurkat cells

Secondary

All lanes:

Goat Anti-Rabbit HRP

Predicted band size: 113 kDa

Observed band size: 85 kDa

true

Exposure time: 5s

This image is courtesy of an Abreview submitted by Adam Szadkowski on 26 January 2006.

Western blot - Anti-Cleaved PARP1 antibody (AB4830)
  • WB

Supplier Data

Western blot - Anti-Cleaved PARP1 antibody (AB4830)

All lanes:

Western blot - Anti-Cleaved PARP1 antibody (ab4830) at 1/1000 dilution

Lane 1:

Jurkat cell lysate at 40 µg

Lane 2:

Jurkat cells treated with Etoposide (1 µM for 16 hours) at 40 µg

Lanes 3 and 5:

HeLa cell lysate at 40 µg

Lane 4:

HeLa cells treated with Etoposide (1 µM for 16 hours) at 40 µg

Lane 6:

HeLa cells treated with Staurosporine (3 µM for 16 hours) at 40 µg

Secondary

All lanes:

Goat anti-Rabbit IgG (H+L) Superclonal™ Recombinant Secondary Antibody, HRP at 1/14000 dilution

Predicted band size: 113 kDa

false

Western blot - Anti-Cleaved PARP1 antibody (AB4830)
  • WB

Supplier Data

Western blot - Anti-Cleaved PARP1 antibody (AB4830)

All lanes:

Western blot - Anti-Cleaved PARP1 antibody (ab4830) at 1/2000 dilution

Lane 1:

THP1 Nuclear Enriched at 30 µg

Lane 2:

HeLa Nuclear Enriched at 30 µg

Lane 3:

KARPAS-299 at 30 µg

Lane 4:

Daudi cell lysate at 30 µg

Secondary

All lanes:

Anti-Rabbit IgG (H+L) Superclonal™ Secondary Antibody, HRP conjugate at 1/2500 dilution

Predicted band size: 113 kDa

false

关键信息

宿主种属

Rabbit

克隆

Polyclonal

亚型

IgG

不含载体蛋白

No

反应种属

Human

应用

WB

applications

免疫原

Synthetic Peptide within Human PARP1. The exact immunogen used to generate this antibody is proprietary information.

P09874

特异性

This antibody specifically recognizes the 85 kDa fragment of cleaved PARP1 and can be used as marker for detecting apoptotic cells. Cleavage site specific antibody, unconjugated. The antiserum was produced against a chemically synthesized peptide corresponding to the N-terminus of cleavage site (214/215) of human PARP1 and will recognize Asp 214 and Gly 215.

反应性数据

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "", "WB-species-notes": "<p></p>" } } }

性能和储存信息

形式
Liquid
纯化工艺
Affinity purification Immunogen
纯化说明
Purified from rabbit serum by sequential epitope-specific chromatography. The antibody has been negatively preadsorbed using a peptide spanning the cleavage site to remove antibody that is reactive with full length PARP1. The final product is generated by affinity chromatography using a peptide corresponding to the PARP1 cleavage site.
存储溶液
pH: 7.3 Preservative: 0.05% Sodium azide Constituents: PBS, 50% Glycerol (glycerin, glycerine), 0.1% BSA
运输条件
Blue Ice
推荐的短期储存条件
+4°C
推荐的长期储存条件
-20°C
分装信息
Upon delivery aliquot
储存信息
Avoid freeze / thaw cycle

补充信息

This supplementary information is collated from multiple sources and compiled automatically.

Cleaved PARP1 also known as cPARP is a fragment of the PARP1 protein an important DNA repair enzyme. The full PARP1 protein has a molecular weight of approximately 116 kDa but after cleavage during apoptosis the cleaved PARP1 fragments typically have a molecular weight of around 89 kDa and 24 kDa. PARP1 is expressed abundantly in the cell nucleus where it plays important roles in maintaining genomic integrity. The cleavage of PARP1 is a common marker for cell apoptosis pointing towards its breakdown in response to cellular stress.
Biological function summary

The enzymatic function of PARP1 involves the transfer of ADP-ribose units from NAD+ to target proteins a process known as ADP-ribosylation. PARP1 operates as a part of the base excision repair complex essential in DNA repair processes. The cleaved form of PARP1 no longer facilitates DNA repair marking a shift towards apoptosis. When PARP1 is cleaved it indicates caspase activity implying cells are undergoing programmed cell death.

Pathways

Cleaved PARP1 is deeply involved in the apoptosis and DNA damage response pathways. In the apoptosis pathway PARP1 interacts with key proteins like caspase-3 which cleaves PARP during apoptosis. In the DNA damage response PARP1 collaborates with proteins such as XRCC1 facilitating the base excision repair pathway important for fixing single-strand DNA breaks. These pathways highlight the dual role of PARP1 in promoting cell survival through repair and cell death via apoptosis.

Cleaved PARP1 serves as an important marker in cancer and neurodegenerative diseases. In cancer research elevated levels of cleaved PARP1 suggest increased rates of apoptosis in response to anti-cancer therapies linking it to tumor suppression efforts. In neurodegenerative diseases excessive activation and cleavage of PARP1 can result in cell death exacerbating conditions like Alzheimer's disease. Through these contexts cleaved PARP1 connects to other therapeutic targets such as caspase proteins in cancer and to potential PARP inhibitors in neurodegenerative disorders.

产品实验方案

For this product, it's our understanding that no specific protocols are required. You can visit:

靶点信息

Poly-ADP-ribosyltransferase that mediates poly-ADP-ribosylation of proteins and plays a key role in DNA repair (PubMed : 17177976, PubMed : 18055453, PubMed : 18172500, PubMed : 19344625, PubMed : 19661379, PubMed : 20388712, PubMed : 21680843, PubMed : 22582261, PubMed : 23230272, PubMed : 25043379, PubMed : 26344098, PubMed : 26626479, PubMed : 26626480, PubMed : 30104678, PubMed : 31796734, PubMed : 32028527, PubMed : 32241924, PubMed : 32358582, PubMed : 33186521, PubMed : 34465625, PubMed : 34737271). Mediates glutamate, aspartate, serine, histidine or tyrosine ADP-ribosylation of proteins : the ADP-D-ribosyl group of NAD(+) is transferred to the acceptor carboxyl group of target residues and further ADP-ribosyl groups are transferred to the 2'-position of the terminal adenosine moiety, building up a polymer with an average chain length of 20-30 units (PubMed : 19764761, PubMed : 25043379, PubMed : 28190768, PubMed : 29954836, PubMed : 35393539, PubMed : 7852410, PubMed : 9315851). Serine ADP-ribosylation of proteins constitutes the primary form of ADP-ribosylation of proteins in response to DNA damage (PubMed : 33186521, PubMed : 34874266). Specificity for the different amino acids is conferred by interacting factors, such as HPF1 and NMNAT1 (PubMed : 28190768, PubMed : 29954836, PubMed : 32028527, PubMed : 33186521, PubMed : 33589610, PubMed : 34625544, PubMed : 34874266). Following interaction with HPF1, catalyzes serine ADP-ribosylation of target proteins; HPF1 confers serine specificity by completing the PARP1 active site (PubMed : 28190768, PubMed : 29954836, PubMed : 32028527, PubMed : 33186521, PubMed : 33589610, PubMed : 34625544, PubMed : 34874266). Also catalyzes tyrosine ADP-ribosylation of target proteins following interaction with HPF1 (PubMed : 29954836, PubMed : 30257210). Following interaction with NMNAT1, catalyzes glutamate and aspartate ADP-ribosylation of target proteins; NMNAT1 confers glutamate and aspartate specificity (By similarity). PARP1 initiates the repair of DNA breaks : recognizes and binds DNA breaks within chromatin and recruits HPF1, licensing serine ADP-ribosylation of target proteins, such as histones (H2BS6ADPr and H3S10ADPr), thereby promoting decompaction of chromatin and the recruitment of repair factors leading to the reparation of DNA strand breaks (PubMed : 17177976, PubMed : 18172500, PubMed : 19344625, PubMed : 19661379, PubMed : 23230272, PubMed : 27067600, PubMed : 34465625, PubMed : 34874266). HPF1 initiates serine ADP-ribosylation but restricts the polymerase activity of PARP1 in order to limit the length of poly-ADP-ribose chains (PubMed : 33683197, PubMed : 34732825, PubMed : 34795260). In addition to base excision repair (BER) pathway, also involved in double-strand breaks (DSBs) repair : together with TIMELESS, accumulates at DNA damage sites and promotes homologous recombination repair by mediating poly-ADP-ribosylation (PubMed : 26344098, PubMed : 30356214). Mediates the poly-ADP-ribosylation of a number of proteins, including itself, APLF, CHFR, RPA1 and NFAT5 (PubMed : 17396150, PubMed : 19764761, PubMed : 24906880, PubMed : 34049076). In addition to proteins, also able to ADP-ribosylate DNA : catalyzes ADP-ribosylation of DNA strand break termini containing terminal phosphates and a 2'-OH group in single- and double-stranded DNA, respectively (PubMed : 27471034). Required for PARP9 and DTX3L recruitment to DNA damage sites (PubMed : 23230272). PARP1-dependent PARP9-DTX3L-mediated ubiquitination promotes the rapid and specific recruitment of 53BP1/TP53BP1, UIMC1/RAP80, and BRCA1 to DNA damage sites (PubMed : 23230272). PARP1-mediated DNA repair in neurons plays a role in sleep : senses DNA damage in neurons and promotes sleep, facilitating efficient DNA repair (By similarity). In addition to DNA repair, also involved in other processes, such as transcription regulation, programmed cell death, membrane repair, adipogenesis and innate immunity (PubMed : 15607977, PubMed : 17177976, PubMed : 19344625, PubMed : 27256882, PubMed : 32315358, PubMed : 32844745, PubMed : 35124853, PubMed : 35393539, PubMed : 35460603). Acts as a repressor of transcription : binds to nucleosomes and modulates chromatin structure in a manner similar to histone H1, thereby altering RNA polymerase II (PubMed : 15607977, PubMed : 22464733). Acts both as a positive and negative regulator of transcription elongation, depending on the context (PubMed : 27256882, PubMed : 35393539). Acts as a positive regulator of transcription elongation by mediating poly-ADP-ribosylation of NELFE, preventing RNA-binding activity of NELFE and relieving transcription pausing (PubMed : 27256882). Acts as a negative regulator of transcription elongation in response to DNA damage by catalyzing poly-ADP-ribosylation of CCNT1, disrupting the phase separation activity of CCNT1 and subsequent activation of CDK9 (PubMed : 35393539). Involved in replication fork progression following interaction with CARM1 : mediates poly-ADP-ribosylation at replication forks, slowing fork progression (PubMed : 33412112). Poly-ADP-ribose chains generated by PARP1 also play a role in poly-ADP-ribose-dependent cell death, a process named parthanatos (By similarity). Also acts as a negative regulator of the cGAS-STING pathway (PubMed : 32315358, PubMed : 32844745, PubMed : 35460603). Acts by mediating poly-ADP-ribosylation of CGAS : PARP1 translocates into the cytosol following phosphorylation by PRKDC and catalyzes poly-ADP-ribosylation and inactivation of CGAS (PubMed : 35460603). Acts as a negative regulator of adipogenesis : catalyzes poly-ADP-ribosylation of histone H2B on 'Glu-35' (H2BE35ADPr) following interaction with NMNAT1, inhibiting phosphorylation of H2B at 'Ser-36' (H2BS36ph), thereby blocking expression of pro-adipogenetic genes (By similarity). Involved in the synthesis of ATP in the nucleus, together with NMNAT1, PARG and NUDT5 (PubMed : 27257257). Nuclear ATP generation is required for extensive chromatin remodeling events that are energy-consuming (PubMed : 27257257).. Poly [ADP-ribose] polymerase 1, processed C-terminus. Promotes AIFM1-mediated apoptosis (PubMed : 33168626). This form, which translocates into the cytoplasm following cleavage by caspase-3 (CASP3) and caspase-7 (CASP7) in response to apoptosis, is auto-poly-ADP-ribosylated and serves as a poly-ADP-ribose carrier to induce AIFM1-mediated apoptosis (PubMed : 33168626).. Poly [ADP-ribose] polymerase 1, processed N-terminus. This cleavage form irreversibly binds to DNA breaks and interferes with DNA repair, promoting DNA damage-induced apoptosis.
See full target information PARP1

文献 (69)

Recent publications for all applications. Explore the full list and refine your search

Frontiers in pharmacology 16:1542204 PubMed40176890

2025

(Sumac) induces autophagic cell death and inhibits mTOR, p38MAPK and STAT3 pathways in 5fluorouracil-resistant colorectal cancer cells.

Applications

Unspecified application

Species

Unspecified reactive species

Zohra Nausheen Nizami,Mazoun Al Azzani,Samah Khaldi,Adil Farooq Wali,Rym Magramane,Shamaa Abdul Samad,Ali H Eid,Kholoud Arafat,Yusra Al Dhaheri,Samir Attoub,Rabah Iratni

Scientific reports 15:2082 PubMed39814799

2025

Cytotoxic mechanisms of pemetrexed and HDAC inhibition in non-small cell lung cancer cells involving ribonucleotides in DNA.

Applications

Unspecified application

Species

Unspecified reactive species

Tobias Solli Iveland,Lars Hagen,Mirta Mittelstedt Leal de Sousa,Nina Beate Liabakk,Per Arne Aas,Animesh Sharma,Bodil Kavli,Geir Slupphaug

Nature communications 15:8002 PubMed39266533

2024

SHANK3 depletion leads to ERK signalling overdose and cell death in KRAS-mutant cancers.

Applications

Unspecified application

Species

Unspecified reactive species

Johanna Lilja,Jasmin Kaivola,James R W Conway,Joni Vuorio,Hanna Parkkola,Pekka Roivas,Michal Dibus,Megan R Chastney,Taru Varila,Guillaume Jacquemet,Emilia Peuhu,Emily Wang,Ulla Pentikäinen,Itziar Martinez D Posada,Hellyeh Hamidi,Arafath K Najumudeen,Owen J Sansom,Igor L Barsukov,Daniel Abankwa,Ilpo Vattulainen,Marko Salmi,Johanna Ivaska

BMC complementary medicine and therapies 23:461 PubMed38102661

2023

Proteomic analysis reveals the molecular mechanism of Astragaloside in the treatment of non-small cell lung cancer by inducing apoptosis.

Applications

Unspecified application

Species

Unspecified reactive species

Jiaqi Liu,Yan Sun,Wenjing Chen,Lingling Deng,Mengmeng Chen,Jingcheng Dong

British journal of cancer 128:2326-2337 PubMed37076563

2023

The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Theodora A Constantin,Anabel Varela-Carver,Kyle K Greenland,Gilberto Serrano de Almeida,Ellen Olden,Lucy Penfold,Simon Ang,Alice Ormrod,Damien A Leach,Chun-Fui Lai,Edward K Ainscow,Ash K Bahl,David Carling,Matthew J Fuchter,Simak Ali,Charlotte L Bevan

Allergologia et immunopathologia 51:99-110 PubMed36916093

2023

CHAC1 exacerbates LPS-induced ferroptosis and apoptosis in HK-2 cells by promoting oxidative stress.

Applications

Unspecified application

Species

Unspecified reactive species

Zhihui Zhou,Hongwei Zhang

Clinical and translational medicine 13:e1153 PubMed36639831

2023

Small molecule Z363 co-regulates TAF10 and MYC via the E3 ligase TRIP12 to suppress tumour growth.

Applications

Unspecified application

Species

Unspecified reactive species

Yan Xiong,Lulu Wang,Shiyao Xu,Beibei Fu,Yuchen Che,Mohamed Y Zaky,Rong Tian,Rui Yao,Dong Guo,Zhou Sha,Feng Lin,Xiaoyuan Lin,Haibo Wu

Breast cancer research : BCR 24:92 PubMed36539893

2022

Ring finger protein 126 promotes breast cancer metastasis and serves as a potential target to improve the therapeutic sensitivity of ATR inhibitors.

Applications

Unspecified application

Species

Unspecified reactive species

You Pan,Yuchao Yang,Rong Huang,Huawei Yang,Qinghua Huang,Yinan Ji,Jingxing Dai,Kun Qiao,Wei Tang,Longgui Xie,Ming Yin,Jun Ouyang,Shipeng Ning,Danke Su

Heliyon 8:e11656 PubMed36458309

2022

PEITC: A resounding molecule averts metastasis in breast cancer cells by regulating PKCδ/Aurora A interplay.

Applications

Unspecified application

Species

Unspecified reactive species

Souvick Biswas,Elizabeth Mahapatra,Salini Das,Madhumita Roy,Sutapa Mukherjee

International journal of molecular sciences 23: PubMed36361570

2022

A Pyrazolate Osmium(VI) Nitride Exhibits Anticancer Activity through Modulating Protein Homeostasis in HepG2 Cells.

Applications

Unspecified application

Species

Unspecified reactive species

Chengyang Huang,Wanqiong Huang,Pengchao Ji,Fuling Song,Tao Liu,Meiyang Li,Hongzhi Guo,Yongliang Huang,Cuicui Yu,Chuanxian Wang,Wenxiu Ni
View all publications

Abcam Product Promise

我们致力于为您的研究提供高质量的试剂,为您科研的每一步提供支持。若我们的产品未能达到预期性能,我们向您提供 Abcam Product Promise 保障。
详情请参阅我们的条款与条件。

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com